Fampridine is NOW Available on the NHS in England | What People with MS Need to Know

This is a landmark moment for people living with multiple sclerosis (MS) in England. After many years of campaigning, fampridine (prolonged-release 4-aminopyridine) is now routinely available on the NHS for eligible people with MS-related walking difficulties. In this video I explain: ✅ Why this NHS decision is so important
✅ How fampridine actually works inside damaged nerves
✅ Why only some people respond to treatment
✅ What to expect during the NHS 2–4 week treatment trial
✅ Who can and cannot take fampridine
✅ Common side effects and important safety information
✅ What happens if you stop taking it
✅ The latest research on real-world benefits beyond walking Fampridine is not a disease-modifying treatment and it is not a cure for MS, but for some people it can make a meaningful difference to walking speed, confidence and day-to-day mobility. Because there is currently no test that predicts who will respond, the only way to know is through a carefully monitored treatment trial with your MS team. If you or someone you know has MS and walking has become more difficult, this video explains everything you need to know before discussing fampridine with your neurologist or MS nurse. Chapters 00:00 A long-awaited NHS change
01:10 What is fampridine?
02:25 How MS disrupts nerve signals
04:15 How fampridine works
06:05 Why some people respond—and others don't
08:45 The latest real-world evidence
10:40 NHS eligibility and treatment trial
13:00 Safety, contraindications and side effects
16:30 Taking fampridine correctly
18:15 What happens if treatment stops?
19:30 A realistic message of hope

Become a supporter of this podcast: https://www.spreaker.com/podcast/beewellwithms-podcast-by-dr-agne-straukiene--5762905/support.